



## NeuroVista Announces First-in-Man Milestone in Australian Clinical Study

**Seattle, WA—June 15, 2010**—NeuroVista Corporation, a developer of innovative medical technologies for the management and treatment of epilepsy, today announced that clinical investigators have implanted the first patient with the NeuroVista® Seizure Advisory System™ in Melbourne, Australia. The neurological implant was performed at St. Vincent’s Hospital by a team lead by Dr. Mark Cook.

“We are very pleased to have achieved this important clinical milestone in collaboration with our Australian investigators,” said John F. Harris, President and Chief Executive Officer of NeuroVista. “This milestone represents a significant achievement as we move our important technology toward commercialization.” In addition to Dr. Mark Cook and his team at St. Vincent’s Hospital, NeuroVista is also working with clinical teams led by Dr. Sam Berkovic at Austin Hospital, and Dr. Terry O’Brien at The Royal Melbourne Hospital.

“The NeuroVista Seizure Advisory System has the potential to greatly improve the quality of life for those living with medically refractory epilepsy,” said Dr. Mark Cook, St. Vincent’s Hospital. “Enabling patients to better understand their likelihood of having a seizure will really be revolutionary. If you can predict seizures this is sort of the holy grail of epilepsy therapy.”

### **About NeuroVista**

NeuroVista is a clinical stage medical device company pioneering new technologies that will revolutionize the management and treatment of epilepsy. Epilepsy is a neurological condition affecting approximately 1% of the U.S. population—more than Parkinson’s disease, multiple sclerosis, and Lou Gehrig’s disease combined. NeuroVista is a privately held company based in Seattle, Washington. For more information, visit [www.neurovista.com](http://www.neurovista.com).